Cellectis CEO calls notion company 'gave away' pipeline 'totally wrong'
Cellectis (CLLS) develops immunotherapies based on gene-edited CAR T-cells. In an exclusive interview with The Fly, the company's CEO Andre Choulika talked about the company's partnerships and pipeline. In a recent research note, a BTIG analyst claimed there is a perception among investors that Cellectis "gave away" its pipeline through partnerships and collaboration agreements. To say "we 'gave away our pipeline through our partnerships' is totally wrong," Choulika said. "We don't think we gave anything away. We just partnered our best products with I think, very good partners." The CEO said the company was looking to push those products further and added Cellectis has been getting great results for self-owned targets like T123, CS1 and C22. "For a small biotech company having three trials ongoing with three different products plus three partner products, I think it's exceptional on our side," he said. "I don't think we gave anything away. The company is becoming strong with our own pipeline of products but also if the partner products work it's a lot of income for the company. Don't forget that the company has $3.8B of potential milestones plus royalties on our partner product pipeline. It could be a lot of potential that could bring the company to a very interesting financial position at the end." "Meet the Company" is The Fly's recurring series of exclusive short interviews with Executive Officers to offer a deeper look inside the company.